Insider Transactions in Q1 2021 at Acceleron Pharma Inc (XLRN)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2021
|
Sujay Kango EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.49%
|
$680,000
$136.75 P/Share
|
|
Mar 02
2021
|
Sujay Kango EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+17.01%
|
$200,000
$40.61 P/Share
|
|
Feb 12
2021
|
Sujay Kango EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
887
-4.57%
|
$115,310
$130.87 P/Share
|
|
Jan 29
2021
|
Francois Nader Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+19.38%
|
-
|
|
Jan 29
2021
|
Laura Hamill Director |
BUY
Grant, award, or other acquisition
|
Direct |
474
+50.0%
|
-
|
|
Jan 29
2021
|
Christopher Hite Director |
BUY
Grant, award, or other acquisition
|
Direct |
930
+50.0%
|
-
|
|
Jan 29
2021
|
Terrence C Kearney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+19.38%
|
-
|
|
Jan 29
2021
|
Kemal Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+50.0%
|
-
|
|
Jan 29
2021
|
Thomas A Mccourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+21.16%
|
-
|
|
Jan 29
2021
|
Karen L. Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+26.23%
|
-
|
|
Jan 29
2021
|
Joseph S Zakrzewski Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+4.49%
|
-
|
|
Jan 29
2021
|
Habib J Dable CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
16,662
+14.47%
|
-
|
|
Jan 29
2021
|
Jay T. Backstrom EVP, Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
5,409
+20.65%
|
-
|
|
Jan 29
2021
|
Sujay Kango EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,409
+21.81%
|
-
|
|
Jan 29
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
4,868
+31.31%
|
-
|
|
Jan 29
2021
|
Adam M Veness SVP, General Counsel and Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
4,868
+18.8%
|
-
|
|
Jan 05
2021
|
Habib J Dable CEO and President |
SELL
Open market or private sale
|
Direct |
4,258
-1.26%
|
$515,218
$121.77 P/Share
|
|
Jan 05
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
1,499
-5.51%
|
$182,878
$122.17 P/Share
|
|
Jan 05
2021
|
Adam M Veness SVP, General Counsel and Sec. |
SELL
Open market or private sale
|
Direct |
2,056
-3.8%
|
$252,888
$123.23 P/Share
|
|
Jan 04
2021
|
Habib J Dable CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,278
-3.67%
|
$406,472
$124.31 P/Share
|
|
Jan 04
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
3,280
-5.97%
|
$406,720
$124.29 P/Share
|
|
Jan 04
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
624
-5.56%
|
$77,376
$124.31 P/Share
|
|
Jan 04
2021
|
Jay T. Backstrom EVP, Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-10.14%
|
$215,140
$124.31 P/Share
|
|
Jan 04
2021
|
Sujay Kango EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-32.03%
|
$1,250,000
$125.07 P/Share
|
|
Jan 04
2021
|
Sujay Kango EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,357
-8.84%
|
$168,268
$124.31 P/Share
|
|
Jan 04
2021
|
Adam M Veness SVP, General Counsel and Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
942
-4.92%
|
$116,808
$124.31 P/Share
|